Erratum: Correction to highly selective and potent thiophenes as PI3K inhibitors with oral antitumor activity (ACS Medicinal Chemistry Letters (2011) 2:11 (809-813) DOI: 10.1021/ml200126j);Highly selective and potent thiophenes as PI3K inhibitors with oral antitumor activity

ACS Medicinal Chemistry Letters

Volumn 2, Issue 11, 2011, Pages 809-813

  Liu, Kevin K C ^a   Zhu, Jinjiang ^a   Smith, Graham L ^a   Yin, Min Jean ^a   Bailey, Simon ^a   Chen, Jeffrey H ^a   Hu, Qiyue ^a   Huang, Qinhua ^a   Li, Chunze ^a   Li, Qing J ^a   Marx, Matthew A ^a   Paderes, Genevieve ^a   Richardson, Paul F ^a   Sach, Neal W ^a   Walls, Marlena ^a   Wells, Peter A ^a   Zou, Aihua ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

antitumor activity; Kinase inhibitor; mTOR; PI3K; thiophene; triazole

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

TETRA;

EID: 80955128586     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300020u     Document Type: Erratum

References (11)

1. Engelman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat. Rev. Genet. 2006, 7, 606-619 (Pubitemid 44100518)
2. Engelman, J. A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations Nat. Rev. Genet. 2009, 9, 550-62
3. Nuss, J. M; Tsuhako, A. L; Anand, N. K. Emerging Therapies based on inhibitors of phosphatidyl-inositol-3-kinases Annu. Rep. Med. Chem. 2009, 44, 339-356
4. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gasdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers Science 2004, 304, 554 (Pubitemid 38541907)
5. Sarbassov, D. D.; Ali, S. M.; Sabatini, D. M. Growing roles for the mTOR pathway Curr. Opin. Cell Biol. 2005, 17, 596
6. Cheng, H.; Bagrodia, S.; Bailey, S.; Edwards, M.; Hoffman, J.; Hu, Q.; Kania, R.; Knighton, D. R.; Marx, M. A.; Ninkovic, S.; Sun, S.; Zhang, E. Med. Chem. Comm. 2010, 1 (2) 139
7. Liu, K. K.-C.; Huang, X.; Bagrodia, S.; Chen, J. H.; Greasley, S.; Cheng, H.; Sun, S.; Knighton, D.; Rodgers, C.; Rafidi, K.; Zou, A.; Xiao, J.; Yan, S. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors Bioorg. Med. Chem. Lett. 2011, 21 (4) 1270-1274
8. Liu, K. K.-C.; Bagrodia, S.; Bailey, S.; Cheng, H.; Chen, H.; Gao, L.; Greasley, S.; Hoffman, J. E.; Hu, Q.; Johnson, T. O.; Knighton, D.; Liu, Z.; Marx, M. A.; Nambu, M. D.; Ninkovic, S.; Pascual, B.; Rafidi, K.; Rodgers, C. M.-L.; Smith, G. L.; Sun, S.; Wang, H.; Yang, A.; Yuan, J.; Zou, A. 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors Bioorg. Med. Chem. Lett. 2010, 20 (20) 6096-6099
9. Kalgutkar, A. S.; Daniels, J. S. 1(Metabolism, Pharmacokinetics and Toxicity of Functional Groups), Carboxylic acids and their bioisosteres RSC Drug Discovery Ser. 2010, 99-167
10. Castano-Mansanet, A. M.; Dominguez-Manzanares, E.; Escribano, A. M.; Fernandez, M. C.; Hornback, W. J; Jimenez-Aguado, A. M.; Tromiczak, E. G.; Wu, Z.; Zarrinmayeh, H.; Zimmerman, D. M. Preparation of thiophene and furan compounds for potentiating glutamate receptor function. WO2005070916, 2005.
11. For a detailed discussion of the synthetic chemistry, see Huang, Q; Richardson, P. F.; Sach, N. W.; Zhu, J; Liu, K. K.-C.; Smith, G. L.; Bowles, D. M. Development of Scalable Syntheses of Selective PI3K inhibitors Org. Process Res. Dev. 2011, 15 (3) 556-564